Samyang Holdings Biopharm
Explore the latest insights on Samyang Holdings Biopharm and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Samyang Holdings Biopharm’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Biokin’s SystImmune Receives Second USD 250 Million Milestone from BMS for Iza‑Bren – Cumulative Payments Reach USD 1.3 Billion with Up to USD 7.1 Billion Still Contingent
Biokin Pharmaceutical (SHA: 688506) announced that its wholly‑owned subsidiary SystImmune has received a second milestone payment of USD 250 million from Bristol-Myers Squibb (BMS) (NYSE: BMY) under their collaboration on…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
